PT00114
Stress-related Neuropsychiatric Disorders (e.g., Depression, Anxiety, PTSD, Addiction)
Key Facts
About Protagenic Therapeutics
Protagenic Therapeutics is a public, clinical-stage biotechnology company developing a novel class of therapeutics based on the Teneurin C-terminal Associated Peptide (TCAP) to regulate the stress response system. Founded in 2015, the company's mission is to address the root cause of stress-related disorders like depression, anxiety, PTSD, and addiction, where current treatments are often inadequate. Its strategy involves building a proprietary TCAP platform to efficiently develop multiple drug candidates for a broad spectrum of CNS indications. The lead candidate, PT00114, is advancing into clinical trials, representing a potentially transformative approach to neuronal health.
View full company profile